Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success publishing date : 2022 - 01 - 04 save search
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.22 -3.06% -7.01% 210K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
MNMD | $9.53 -3.54% -3.67% 780K
|
n/a
|
| O: -1.32%
H: 1.33%
C: -1.33%
trial phase 1 phase 2 phase 3
Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Published: 2022-01-04 (Crawled : 19:00) - biospace.com/
ENSC | $0.6298 -2.46% -3.23% 120K
|
Health Technology
|
| O: 4.43%
H: 4.23%
C: -8.93%
pf614 trial opioid bioscience
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.22 -3.06% -7.01% 210K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.